R—FND方案与R—CHOP方案治疗MALT淋巴瘤疗效评价.docVIP

R—FND方案与R—CHOP方案治疗MALT淋巴瘤疗效评价 　　【摘要】 目的：评价利妥昔单抗（R）联合FND方案与CHOP方案治疗MALT淋巴瘤的疗效与安全性。方法：将入组初治MALT淋巴瘤患者随机分入CHOP方案组及FND方案组，并根据是否加用利妥昔单抗分为4组：FND组、R-FND组、CHOP组、R-CHOP组。治疗后定期随访，评估无失败生存（FFS）、总生存（OS）。结果：54例患者中，FND组与CHOP组比较，治疗总有效率分别为57.1%、46.2%（P=0.25），R-FND组与R-CHOP组比较，治疗总有效率分别为92.3%、85.7%（P=0.19）。中位随访32.4个月，FND组与CHOP组3年FFS率分别为35.9%和34.7%（P=0.39）；R-FND组与R-CHOP组3年FFS率分别为69.8%和75.5%（P=0.01）。结论：FND与CHOP方案疗效相当。两方案联合利妥昔单抗，有效率差异不明显，但R-CHOP方案在无失败生存更具优势，且耐受性优于R-FND方案。 　　【关键词】 MALT淋巴瘤； 利妥昔单抗； 氟达拉滨； CHOP； FND 　　The Efficacy of R-FND Regimen and R-CHOP Regimen in the Treatment of MALT Lymphoma/WANG Kun，XUE Hong-wei，ZHAO Yan-wei，et al.//Medical Innovation of China，2014，11（12）：041-043 　　【Abstract】 Objective：To study the efficacy of rituximab （R） plus FND chemotherapy and rituximab plus CHOP chemotherapy for MALT lymphoma.Method：The group initially treated MALT lymphoma patients were randomly divided into the CHOP group and the FND group.According to whether the addition of rituximab were divided into 4 groups：FND group，R-FND group，CHOP group，R-CHOP group.Regular follow-up after treatment，failure free survival（FFS），overall survival （OS） were evaluated.Result：There were 54 patients enrolled onto the study.Overall response rates were 57.1%，46.2% for FND group and CHOP group（P=0.25），92.3% and 85.7% for R-FND group and R-CHOP group（P=0.19）.After a median follow-up of 32.4 months，3-year FFS were 35.9%，34.7% for FND group and CHOP group（P=0.39）. And 69.8%，75.5% for R-FND group and R-CHOP group（P=0.01）.Conclusion：FND regimen has same efficacy to CHOP regimen in overall response rates and FFS.But R-CHOP regimen is superior to R-FND regimen in terms of 3-year FFS.In addition，R-CHOP regimen has a better risk-benefit ratio compared with R-FND regimen. 　　【Key words】 MALT Lymphoma； Rituximab； Fludarabine； CHOP； FND 　　First-author’s address：The Affiliated Hospital of Qingdao University，Qingdao 266003，China 　　doi：10.3969/j.issn.1674-4985.2014.12.015 　　黏膜相关淋巴组织边缘区B细胞淋巴瘤（MALT lymphoma）现仍无标准化疗方案，既往临床